The chromogranin-secretogranin family

New England Journal of Medicine

Volumn 348, Issue 12, 2003, Pages 1134-1149

  Taupenot, Laurent ^a,b   Harper, Kimberly L ^a,b   O'Connor, Daniel T ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN; CHROMOGRANIN A; NEUROPEPTIDE; PEPTIDE HORMONE;

AUTOCRINE EFFECT; HUMAN; NERVE CELL; NEUROSECRETORY CELL; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN STRUCTURE; REVIEW; SECRETORY GRANULE; TRANSCRIPTION REGULATION;

CATECHOLAMINES; CHROMOGRANIN A; CHROMOGRANINS; HUMANS; HYPERTENSION; KIDNEY FAILURE; NEOPLASMS; NEUROPEPTIDES; PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037456743     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra021405     Document Type: Review

References (145)

1. O'Connor DT. Chromogranin: widespread immunoreactivity in polypeptide hormone producing tissues and in serum. Regul Pept 1983;6:263-80.
2. O'Connor DT, Burton D, Deftos LJ. Chromogranin A: immunohistology reveals its universal occurrence in normal polypeptide hormone producing endocrine glands. Life Sci 1983;33:1657-63.
3. O'Connor DT, Frigon RP. Chromogranin A, the major catecholamine storage vesicle soluble protein: multiple size forms, subcellular storage, and regional distribution in chromaffin and nervous tissue elucidated by radioimmunoassay. J Biol Chem 1984;259:3237-47.
4. O'Connor DT, Klein RL, Thureson-Klein AK, Barbosa JA. Chromogranin A: localization and stoichiometry in large dense core catecholamine storage vesicles from sympathetic nerve. Brain Res 1991;567:188-96.
5. Banks P, Helle KB. The release of protein from the stimulated adrenal medulla. Biochem J 1965;97:40C-41C.
6. Helle KB. Some chemical and physical properties of the soluble protein fraction of bovine adrenal chromaffin granules. Mol Pharmacol 1966;2:298-310.
7. Lee RW, Huttner WB. Tyrosine-O-sulfated proteins of PC12 pheochromocytoma cells and their sulfation by a tyrosylprotein sulfotransferase. J Biol Chem 1983;258:11326-34.
8. Posa P, Zanini A. Characterization of adenohypophysial polypeptides by two-dimensional gel electrophoresis. II. Sulfated and glycosylated polypeptides. Mol Cell Endocrinol 1981;24:181-93.
9. Fischer-Colbrie R, Laslop A, Kirchmair R. Secretogranin II: molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin. Prog Neurobiol 1995;46:49-70.
10. Huttner WB, Gerdes HH, Rosa P. The granin (chromogranin/secretogranin) family. Trends Biochem Sci 1991;16:27-30.
11. Ottiger HP, Battenberg EF, Tsou AP, Bloom FE, Sutcliffe JG. 1B1075: A brain- and pituitary-specific mRNA that encodes a novel chromogranin/secretogranin-like component of intracellular vesicles. J Neurosci 1990;10:3135-47.
12. Krisch K, Buxbaum P, Horvat G, et al. Monoclonal antibody HISL-19 as an immunocytochemical probe for neuroendocrine differentiation: its application in diagnostic pathology. Am J Pathol 1986;123:100-8.
13. Mbikay M, Seidah NG, Chretien M. Neuroendocrine secretory protein 7B2: structure, expression and functions. Biochem J 2001;357:329-42.
14. Ischia R, Lovisetti-Scamihorn P, Hogue-Angeletti R, Wolkersdorfer M, Winkler H, Fischer-Colbrie R. Molecular cloning and characterization of NESP55, a novel chromogranin-like precursor of a peptide with 5-HT1B receptor antagonist activity. J Biol Chem 1997;272:11657-62.
15. O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986;314: 1145-51.
16. Stridsberg M, Oberg K, Li Q, Engstrom U, Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995;144:49-59.
17. Nobels FR, Kwekkeboom DJ, Bouillon R, Lamberts SW. Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur J Clin Invest 1998;28:431-40.
18. Reiffen FU, Gratzl M. Chromogranins, widespread in endocrine and nervous tissue, bind Ca2+. FEBS Lett 1986;195:327-30.
19. Grimes M, Iacangelo A, Eiden LE, Godfrey B, Herbert E. Chromogranin A: the primary structure deduced from cDNA clones reveals the presence of pairs of basic amino acids. Ann N Y Acad Sci 1987;493:351-78.
20. Konecki DS, Benedum UM, Gerdes HH, Huttner WB. The primary structure of human chromogranin A and pancreastatin. J Biol Chem 1987;262:17026-30.
21. Gorr SU, Shioi J, Cohn DV. Interaction of calcium with porcine adrenal chromogranin A (secretory protein-I) and chromogranin B (secretogranin I). Am J Physiol 1989;257:E247-E254.
22. Gerdes HH, Rosa P, Phillips E, et al. The primary structure of human secretogranin II, a widespread tyrosine-sulfated secretory granule protein that exhibits low pH- and calcium-induced aggregation. J Biol Chem 1989;264:12009-15.
23. Yoo SH, Albanesi JP. High capacity, low affinity Ca2+ binding of chromogranin A: relationship between the pH-induced conformational change and Ca2+ binding property. J Biol Chem 1991;266:7740-5.
24. Videen JS, Mezger MS, Chang YM, O'Connor DT. Calcium and catecholamine interactions with adrenal chromogranins: comparison of driving forces in binding and aggregation. J Biol Chem 1992;267:3066-73.
25. Mahata SK, Kozak CA, Szpirer J, et al. Dispersion of chromogranin/secretogranin secretory protein family loci in mammalian genomes. Genomics 1996;33:135-9.
26. Simon JP, Aunis D. Biochemistry of the chromogranin A protein family. Biochem J 1989;262:1-13.
27. Winkler H, Fischer-Colbrie R. The chromogranins A and B: the first 25 years and future perspectives. Neuroscience 1992;49:497-528.
28. O'Connor DT, Wu H, Gill BM, et al. Hormone storage vesicle proteins: transcriptional basis of the widespread neuroendocrine expression of chromogranin A, and evidence of its diverse biological actions, intracellular and extracellular. Ann N Y Acad Sci 1994;733:36-45.
29. Wu H, Kozansky DJ, Webster NJ, O'Connor DT. Cell type-specific gene expression in the neuroendocrine system: a neuroendocrine-specific regulatory element in the promoter of chromogranin A, a ubiquitous secretory granule core protein. J Clin Invest 1994;94:118-29.
30. Wu H, Mahata SK, Mahata M, Webster NJ, Parmer RJ, O'Connor DT. A functional cyclic AMP response element plays a crucial role in neuroendocrine cell type-specific expression of the secretory granule protein chromogranin A. J Clin Invest 1995;96:568-78.
31. Mahapatra NR, Mahata M, Datta AK, et al. Neuroendocrine cell type-specific and inducible expression of the chromogranin B gene: crucial role of the proximal promoter. Endocrinology 2000;141:3668-78.
32. Mahata SK, Mahata M, Livsey CV, Gerdes HH, Huttner WB, O'Connor DT. Neuroendocrine cell type-specific and inducible expression of the secretogranin II gene: crucial role of cyclic adenosine monophosphate and serum response elements. Endocrinology 1999;140:739-49.
33. Nolan EM, Cheung TC, Burton DW, Deftos LJ. Transcriptional regulation of the human chromogranin A gene by its 5′ distal regulatory element: novel effects of orientation, structure, flanking sequences, and position on expression. Mol Cell Endocrinol 1996;124:51-62.
34. Desmoucelles C, Vaudry H, Eiden LE, Anouar Y. Synergistic action of upstream elements and a promoter-proximal CRE is required for neuroendocrine cell-specific expression and second-messenger regulation of the gene encoding the human secretory protein secretogranin II. Mol Cell Endocrinol 1999;157:55-66.
35. Taupenot L, Mahata SK, Wu H, O'Connor DT. Peptidergic activation of transcription and secretion in chromaffin cells: cis and trans signaling determinants of pituitary adenylyl cyclase-activating polypeptide (PACAP). J Clin Invest 1998;101:863-76.
36. Taupenot L, Mahata M, Mahata SK, O'Connor DT. Time-dependent effects of the neuropeptide PACAP on catecholamine secretion: stimulation and desensitization. Hypertension 1999;34:1152-62.
37. Mahata SK, Mahata M, Wu H, Parmer RJ, O'Connor DT. Neurotrophin activation of catecholamine storage vesicle protein gene expression: signaling to chromogranin A biosynthesis. Neuroscience 1999;88:405-24.
38. Rozansky DJ, Wu H, Tang K, Parmer RJ, O'Connor DT. Glucocorticoid activation of chromogranin A gene expression: identification and characterization of a novel glucocorticoid response element. J Clin Invest 1994;94:2357-68.
39. Kelly RB. Pathways of protein secretion in eukaryotes. Science 1985;230:25-32.
40. Halban PA, Irminger JC. Sorting and processing of secretory proteins. Biochem J 1994;299:1-18.
41. Arvan P, Castle D. Sorting and storage during secretory granule biogenesis: looking backward and looking forward. Biochem J 1998;332:593-610.
42. Yoo SH. pH-Dependent association of chromogranin A with secretory vesicle membrane and a putative membrane binding region of chromogranin A. Biochemistry 1993;32:8213-9.
43. Chanat E, Huttner WB. Milieu-induced, selective aggregation of regulated secretory proteins in the trans-Golgi network. J Cell Biol 1991;115:1505-19.
44. Cool DR, Normant E, Shen F, et al. Carboxypeptidase E is a regulated secretory pathway sorting receptor: genetic obliteration leads to endocrine disorders in Cpe(fat) mice. Cell 1997;88:73-83.
45. Loh YP, Snell CR, Cool DR. Receptor-mediated targeting of hormones to secretory granules: role of carboxypeptidase E. Trends Endocrinol Metab 1997;8:130-7.
46. Thiele C, Gerdes HH, Huttner WB. Protein secretion: puzzling receptors. Curr Biol 1997;7:R496-R500.
47. Thiele C, Huttner WB. Protein and lipid sorting from the trans-Golgi network to secretory granules - recent developments. Semin Cell Dev Biol 1998;9;511-6.
48. Tooze SA, Martens GJ, Huttner WB. Secretory granule biogenesis: rafting to the SNARE. Trends Cell Biol 2001;11;116-22.
49. Chanat E, Weiss U, Huttner WB, Tooze SA. Reduction of the disulfide bond of chromogranin B (secretogranin I) in the transGolgi network causes its missorting to the constitutive secretory pathways. EMBO J 1993;12:2159-68.
50. Chanat E, Weiss U, Huttner WB. The disulfide bond in chromogranin B, which is essential for its sorting to secretory granules, is not required for its aggregation in the trans-Golgi network. FEBS Lett 1994;351:225-30.
51. Kromer A, Glombik MM, Huttner WB, Gerdes HH. Essential role of the disulfide-bonded loop of chromogranin B for sorting to secretory granules is revealed by expression of a deletion mutant in the absence of endogenous granin synthesis. J Cell Biol 1998;140:1331-46.
52. Glombik MM, Kromer A, Salm T, Huttner WB, Gerdes HH. The disulfide-bonded loop of chromogranin B mediates membrane binding and directs sorting from the transGolgi network to secretory granules. EMBO J 1999;18:1059-70.
53. Watkinson A, Dockray GJ. Functional control of chromogranin A and B concentrations in the body of the rat stomach. Regul Pept 1992;40:51-61.
54. Bargsten G, Grube D. Serotonin storage and chromogranins: an experimental study in rat gastric endocrine cells. J Histochem Cytochem 1992;40:1147-55.
55. Iacangelo AL, Eiden LE. Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway. Regul Pept 1995;58:65-88.
56. Helle KB, Reed RK, Ehrhart M, Aunis D, Hogue Angeletti R. Chromogranin A: osmotically active fragments and their susceptibility to proteolysis during lysis of the bovine chromaffin granules. Acta Physiol Scand 1990;138:565-74.
57. Huttner WB, Natori S. Regulated secretion: helper proteins for neuroendocrine secretion. Curr Biol 1995;5:242-5.
58. Kim T, Tao-Cheng JH, Eiden LE, Loh YP. Chromogranin A, an "on/off" switch controlling dense-core secretory granule biogenesis. Cell 2001;106:499-509.
59. Dillen L, Miserez B, Claeys M, Aunis D, De Potter W. Posttranslational processing of proenkephalins and chromogranins/secretogranins. Neurochem Int 1993;22:315-52.
60. Eskeland NL, Zhou A, Dinh TQ, et al. Chromogranin A processing and secretion: specific role of endogenous and exogenous prohormone convertases in the regulated secretory pathway. J Clin Invest 1996;98:148-56.
61. Laslop A, Weiss C, Savaria D, et al. Proteolytic processing of chromogranin B and secretogranin II by prohormone convertases. J Neurochem 1998;70:374-83.
62. Jiang Q, Taupenot L, Mahata SK, et al. Proteolytic cleavage of chromogranin A (CgA) by plasmin: selective liberation of a specific bioactive CgA fragment that regulates catecholamine release. J Biol Chem 2001;276:25022-9.
63. Westphal CH, Muller L, Zhou A, et al. The neuroendocrine protein 7B2 is required for peptide hormone processing in vivo and provides a novel mechanism for pituitary Cushing's disease. Cell 1999;96:689-700.
64. Tatemoto K, Efendic S, Mutt V, Makk G, Feistner GJ, Barchas JD. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 1986;324:476-8.
65. Sanchez-Margalet V, Lucas M, Goberna R. Pancreastatin: further evidence for its consideration as a regulatory peptide. J Mol Endocrinol 1996;16;1-8.
66. Sanchez-Margalet V, Gonzalez-Yanes C, Santos-Alvarez J, Najib S. Pancreastatin: biological effects and mechanisms of action. Adv Exp Med Biol 2000;482:247-62.
67. Cadman PE, Rao F, Mahata SK, O'Connor DT. Studies of the disglycemic peptide, pancreastatin, using a human forearm model. Ann N Y Acad Sci 2002;971:528-9.
68. Aardal S, Helle KB, Elsayed S, Reed RK, Serck-Hanssen G. Vasostatins, comprising the N-terminal domain of chromogranin A, suppress tension in isolated human blood vessel segments. J Neuroendocrinol 1993;5:405-12.
69. Ratti S, Curnis F, Longhi R, et al. Structure-activity relationships of chromogranin A in cell adhesion: identification of an adhesion site for fibroblasts and smooth muscle cells. J Biol Chem 2000;275:29257-63.
70. Russell J, Gee P, Liu SM, Angeletti RH. Inhibition of parathyroid hormone secretion by amino-terminal chromogranin peptides. Endocrinology 1994;135:337-42.
71. Fasciotto BH, Trauss CA, Greeley GH, Cohn DV. Parastatin (porcine chromogranin A347-419), a novel chromogranin A-derived peptide, inhibits parathyroid cell secretion. Endocrinology 1993;133:461-6.
72. Wand GS, Takiyyuddin M, O'Connor DT, Levine MA. A proposed role for chromogranin A as a glucocorticoid-responsive autocrine inhibitor of proopiomelanocortin secretion. Endocrinology 1991;128:1345-51.
73. Simon JP, Bader MF, Aunis D. Secretion from chromaffin cells is controlled by chromogranin A-derived peptides. Proc Natl Acad Sci U S A 1988;85:1712-6.
74. Mahata SK, O'Connor DT, Mahata M, et al. Novel autocrine feedback control of carecholamine release: a discrete chromogranin A fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 1997;100:1623-33.
75. Taupenot L, Mahata SK, Mahata M, Parmer RJ, O'Connor DT. Interaction of the catecholamine release-inhibitory peptide catestatin (human chromogranin A(352-372)) with the chromaffin cell surface and Torpedo electroplax: implications for nicotinic cholinergic antagonism. Regul Pept 2000;95:9-17.
76. Mahata SK, Mahata M, Parmer RJ, O'Connor DT. Densensitization of catecholamine release: the novel catecholamine release-inhibitory peptide catestatin (chromogranin a344-364) acts at the receptor to prevent nicotinic cholinergic tolerance. J Biol Chem 1999;274:2920-8.
77. O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens 2002;20:1335-45.
78. Kong C, Gill BM, Rahimpour R, et al. Secretoneurin and chemoattractant receptor interactions. J Neuroimmunol 1998;88:91-8.
79. Helle KB. Vasostatins: vascular targets. Adv Exp Med Biol 2000;482:225-38.
80. Takiyyuddin MA, Cervenka JH, Sullivan PA, et al. Is physiologic sympathoadrenal catecholamine release exocytotic in humans? Circulation 1990;81:185-95.
81. Takiyyuddin MA, Cervenka JH, Pandian MR, Stuenkel CA, Neumann HP, O'Connor DT. Neuroendocrine sources of chromogranin-A in normal man: clues from selective stimulation of endocrine glands. J Clin Endocrinol Metab 1990;71:360-9.
82. Lugardon K, Kaffner R, Goumon Y, et al. Antibacterial and antifungal activities of vasostatin-1, the N-terminal fragment of chromogranin A. J Biol Chem 2000;275:10745-53.
83. Lugardon K, Chasserot-Golaz S, Kieffer AE, et al. Structural and biological characterization of chromofungin, the antifungal chromogranin A-(47-66)-derived peptide. J Biol Chem 2001;276:35875-82.
84. Strub JM, Garcia-Sablone P, Lonning K, et al. Processing of chromogranin B in bovine adrenal medulla: identification of secretolytin, the endogenous, C-terminal fragment of residues 614-626 with antibacterial activity. Eur J Biochem 1995;229:356-68.
85. Taupenot L, Ciesielski-Treska J, Ulrich G, Chasserot-Golaz S, Aunis D, Bader MF. Chromogranin A triggers a phenotypic transformation and the generation of nitric oxide in brain microglial cells. Neuroscience 1996;72:377-89.
86. Ciesielski-Treska J, Ulrich G, Taupenot L, et al. Chromogranin A induces a neurotoxic phenotype in brain microglial cells. J Biol Chem 1998;273:14339-46.
87. Ciesielski-Treska J, Ulrich G, Chasserot-Golaz S, et al. Mechanisms underlying neuronal death induced by chromogranin A-activated microglia. J Biol Chem 2001;276:13113-20.
88. Wiedermann CJ. Secretoneurin: a functional neuropeptide in health and disease. Peptides 2000;21:1289-98.
89. Somogyi P, Hodgson AJ, DePotter RW, et al. Chromogranin immunoreactivity in the central nervous system: immunochemical characterisation, distribution and relationship to catecholamine and enkephalin pathways. Brain Res 1984;320:193-230.
90. Munoz DG, Kobylinski L, Henry DD, George DH. Chromogranin A-like immunoreactivity in the human brain: distribution in bulbar medulla and cerebral cortex. Neuroscience 1990;34:533-43.
91. Woulfe J, Deng D, Munoz D. Chromogranin A in the central nervous system of the rat: pan-neuronal expression ofits mRNA and selective expression of the protein. Neuropeptides 1999;33:285-300.
92. O'Connor DT, Bernstein KN. Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. N Engl J Med 1984;311:764-70.
93. O'Connor DT, Pandlan MR, Carlton E, Cervenka JH, Hslao RJ. Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. Clin Chem 1989;35:1631-7.
94. Syversen U, Jacobsen MB, O'Connor DT, Ronning K, Waldum HL. Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia. Neuropeptides 1994;26:201-6.
95. Degorce F, Goumon Y, Jacquemart L, et al. A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245). Br J Cancer 1999;79:65-71.
96. Boomsma, F, Bhaggoe UM, Man in 't Veld AJ, Schalekamp MA. Sensitivity and specificity of a new ELISA method for determination of chromogranin A in the diagnosis of pheochromocytoma and neuroblastoma. Clin Chim Acta 1995;239:57-63.
97. Tsao KC, Wu JT. Development of an ELISA for the detection of serum chromogranin A (CgA) in prostate and non-neuroendocrine carcinomas. Clin Chim Acta 2001;313:21-9.
98. Ischia R, Gasser RW, Fischer-Colbrie R, et al. Levels and molecular properties of secretoneurin-immunoreactivity in the serum and urine of control and neuroendocrine tumor patients. J Clin Endocrinol Metab 2000;85:355-60.
99. Wu TL, Chang CP, Tsao KC, Sun CF, Wu JT. Development of a microplate assay for serum chromogranin A (CgA): establishment of normal reference values and detection of elevated CgA in malignant diseases. J Clin Lab Anal 1999;13:312-9.
100. Rao F, Keiser HR, O'Connor DT. Malignant pheochromocytoma: chromaffin granule transmitters and response to treatment. Hypertension 2000;36:1045-52.
101. Ferrari L, Seregni E, Bajetta E, Martinetti A, Bombardieri E. The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours. Anticancer Res 1999;19:3415-27.
102. Hsiao RJ, Seeger PC, Yu AL, O'Connor DT. Chromogranin A in children with neuroblastoma: serum concentration parallels disease stage and predicts survival. J Clin Invest 1990;85:1555-9.
103. Stabile BE, Howard TJ, Passaro E Jr, O'Connor DT. Source of plasma chromogranin A elevation in gastrinoma patients. Arch Surg 1990;125:451-3.
104. Sanduleanu S, De Bruine A, Stridsberg M, et al. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest 2001;31:802-11.
105. Sekiya K, Ghatei MA, Salahuddin MJ, et al. Production of GAWK (chromogranin-B 420-493)-like immunoreactivity by endocrine tumors and its possible diagnostic value. J Clin Invest 1989;83:1834-42.
106. Yasuda D, Iguchi H, Funakoshi A, et al. Comparison of plasma pancreastatin and GAWK concentrations, presumed processing products of chromogranin A and B, in plasma of patients with pancreatic islet cell tumors. Horm Metab Res 1993;25:593-5.
107. Vieau D, Rojas-Miranda A, Verley JM, Lenne L, Bertagna X. The secretory granule peptides 7B2 and CCB are sensitive biochemical markers of neuro-endocrine bronchial tumours in man. Clin Endocrinol (Oxf) 1991;35:319-25.
108. Suzuki H, Ghatei MA, Williams SJ, et al. Production of pituitary protein 7B2 immunoreactivity by endocrine tumors and its possible diagnostic value. J Clin Endocrinol Metab 1986;63:758-65.
109. Natori S, Iguchi H, Ohashi M, Nawata H. Plasma 7B2 (a novel pituitary protein) immunoreactivity concentrations in patients with various endocrine disorders. Endocrinol Jpn 1988;35:651-4.
110. Iguchi H, Yasuda D, Yamada Y, et al. 7B2, A possible marker for nonfunctioning pancreatic islet cell tumor. Horm Metab Res 1991;23:486-9.
111. Ohashi M, Natori S, Fujio N, Iguchi H, Nawata H. Secretory protein 7B2: a novel tumor marker of medullary carcinoma of the thyroid. Horm Metab Res 1990;22:114-6.
112. Iguchi H, Hara N, Hayashi I, Ohta M, Bloom SR, Chretien M. Elevation of a novel pituitary protein (7B2) in the plasma in small cell carcinoma of the lung. Eur J Cancer Clin Oncol 1989;25:1225-32.
113. Hsiao RJ, Neumann HP, Parmer RJ, Barbosa JA, O'Connor DT. Chromogranin A in familial pheochromocytoma: diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating twocompartment distribution. Am J Med 1990;88:607-13.
114. Neumann HPH, Berger DP, Sigmund G, et al. Pheochromocytomas, multiple endocrine neoplasia type 2 and von Hippel-Lindau disease. N Engl J Med 1993;329:1531-8. [Erratum, N Engl J Med 1994;331:1535.]
115. Hsiao RJ, Parmer RJ, Takiyyuddin MA, O'Connor DT. Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine (Baltimore) 1991;70:33-45.
116. Hsiao RJ, Mezger MS, O'Connor DT. Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int 1990;37:955-64.
117. Canale MP, Bravo EL. Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction. J Clin Endocrinol Metab 1994;78:1139-44.
118. Kailasam MT, Parmer RJ, Stone RA, et al. Factitious pheochromocytoma: novel mimickry by Valsalva maneuver and clues to diagnosis. Am J Hypertens 1995;8:651-5.
119. Stridsberg M, Husebye ES. Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma. Eur J Endocrinol 1997;136:67-73.
120. Granberg D, Stridsberg M, Seensalu R, et al. Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1999;84:2712-7.
121. Syversen U, Jacobsen MB, Hanssen LE, O'Connor DT, Waldum HL. Chromogranin A and pancreastatin-like immunoreactivity in human carcinoid disease. Eur J Gastroenterol Hepatol 1993;5:1043-50.
122. Lamberts SW, Hofland LJ, Nobels FR, Neuroendocrine tumor markers. Front Neuroendocrinol 2001;22:309-39.
123. Simonsson M, Eriksson S, Hakanson R, et al. Endocrine cells in the human oxyntic mucosa: a histochemical study. Scand J Gastroenterol 1988;23:1089-99.
124. Nanes MS, O'Connor DT, Marx SJ. Plasma chromogranin-A in primary hyperparathyroidism. J Clin Endocrinol Metab 1989;69:950-5.
125. Sobol RE, O'Connor DT, Addison J, Suchocki K, Royston I, Deftos LJ. Elevated serum chromogranin A concentrations in small-cell lung carcinoma. Ann Intern Med 1986;105:698-700.
126. Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjolnerod OK, Waldum HL. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Prostate 1997;30:1-6.
127. Wu JT, Erickson AJ, Tsao KC, Wu TL, Sun CF. Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages. Ann Clin Lab Sci 2000;30:175-8.
128. Deftos LJ, Abrahamsson PA. Granins and prostate cancer. Urology 1998;51:Suppl:141-5.
129. Krijnen JL, Bogdanowicz JF, Seldenrijk CA, Mulder PG, van der Kwast TH. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 1997;158:171-4.
130. Syversen U, Halvorsen T, Marvik R, Waldum HL. Neuroendocrine differentiaton in colorectal carcinomas. Eur J Gastroenterol Hepatol 1995;7:667-74.
131. Giovanella L, Marelli M, Ceriani L, Giardina G, Garancini S, Colombo L. Evaluation of chromogranin A expression in serum and tissues of breast cancer patients. Int J Biol Markers 2001;16:268-72.
132. DeStephano DB, Lloyd RV, Pike AM, Wilson BS. Pituitary adenomas: an immunohistochemical study of hormone production and chromogranin localization. Am J Pathol 1984;116:464-72.
133. Deftos LJ, O'Connor DT, Wilson CB, Fitzgerald PA. Human pituitary tumors secrete chromogranin-A. J Clin Endocrinol Metab 1989;68:869-72.
134. Sobol RE, Memoli V, Deftos LJ. Hormone-negative, chromogranin A-positive endocrine tumors. N Engl J Med 1989;320:444-7.
135. Takiyyuddin MA, Baron AD, Cervenka JH, et al. Suppression of chromogranin-A release from neuroendocrine sources in man: pharmacological studies. J Clin Endocrinol Metab 1991;72:616-22.
136. Dimsdale JE, O'Connor DT, Ziegler M, Mills P. Chromogranin A correlates with norepinephrine release rate. Life Sci 1992;51:519-25.
137. Takiyyuddin MA, Parmer RJ, Kailasam MT, et al. Chromogranin A in human hypertension: influence of heredity. Hypertension 1995;26:213-20.
138. Sanchez-Margalet V, Valle M, Lobon JA, et al. Increased plasma pancreastatin-like immunoreactivity levels in non-obese patients with essential hypertension. J Hypertens 1995;13:251-8.
139. O'Connor DT, Cervenka JH, Stone RA, et al. Chromogranin A immunoreactivity in human cerebrospinal fluid: properties, relationship to noradrenergic neuronal activity, and variation in neurologic disease. Neuroscience 1993;56:999-1007.
140. Munoz DG. Chromogranin A-like immunocreactive neurites are major constituents of senile plaques. Lab Invest 1991;64:826-32.
141. Yasuhara O, Kawamata T, Aimi Y, McGeer EG, McGeer PL. Expression of chromogranin A in lesions in the central nervous system from patients with neurological diseases. Neurosci Lett 1994;170:13-6.
142. Landen M, Grenfeldt B, Davidsson P, et al. Reduction of chromogranin A and B but not C in the cerebrospinal fluid in subjects with schizophrenia. Eur Neuropsychopharmacol 1999;9:311-5.
143. Kitao Y, Inada T, Arinami T, et al. A contribution to genome-wide association studies: search for susceptibility loci for schizophrenia using DNA microsatellite markers on chromosomes 19, 20, 21 and 22. Psychiatr Genet 2000;10:139-43.
144. Zhang B, Tan Z, Zhang C, et al. Polymorphisms of chromogranin B gene associated with schizophrenia in Chinese Han population. Neurosci Lett 2002;323:229-33.
145. Corti A, Ferrari R, Ceconi C. Chromogranin A and tumor necrosis factor-alpha (TNF) in chronic heart failure. Adv Exp Med Biol 2000;482:351-9.